A woman who could lose her sight has been given permission for a test case at the High Court to try to get an NHS Trust to fund her treatment. Warwickshire Primary Care Trust refused to pay for Patricia Meadow's eye treatment, even though the drug is available in other areas. Ms Meadows, 65, from Stratford-on-Avon, suffers diseases in both eyes. The trust took a "resource-based" decision not to fund treatment, the court heard. Ms Meadows suffers from wet age-related macular degeneration (AMD) in her left eye, and dry intermediate AMD in her right. Matter of months There is no treatment for the dry condition, but there is hope that a course of the drug ranibizumab (trade name Lucentis) will save the sight in her left eye. The High Court heard from her lawyers that objective medical evidence shows a course of the drug has up to a 95% chance of arresting her eyesight deterioration. They said there was also a chance of it improving her vision and without treatment she could lose her sight in a matter of months. Her case is being backed by the Royal National Institute of Blind People. Mr Justice Undershill gave permission for a judicial review to be heard within a matter of weeks. Not 'cost-effective' He heard from Ms Meadows's council, Ian Wise, who said the trust's policy of not routinely funding treatment, and their decision that she was not an exceptional case, was "unlawful and irrational". David Lock, appearing for the PCT, said the trust had taken a "resource-based" decision. He said Novartis, the manufacturer of Lucentis, was refusing to provide the support recommended by the National Institute for Health and Clinical Excellence (Nice). He said: "Without the manufacturers support, Nice has clearly advised that this is not a cost-effective treatment. He said the PCT had to balance a budget of �668m and it was impossible to meet all the needs of patients.
| 
Breakfast 
E-mail this to a friend 
Printable version 
BBC News
Bookmark with:
What are these?